KRS Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

KRS Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-27,941	Closed	-$2.85M	–	117
2023 Q2	$2.85M	Sell	27,941 -200	-0.7%	-$18.9K	2.85%	5
2023 Q1	$2.56M	Hold	28,141	–	–	2.88%	5
2022 Q4	$1.07M	Hold	28,141	–	–	1.46%	14
2022 Q3	$707K	Hold	28,141	–	–	0.97%	25
2022 Q2	$855K	Hold	28,141	–	–	1.22%	20
2022 Q1	$921K	Sell	28,141 -4,700	-14%	-$139K	1%	25
2021 Q4	$866K	Buy	+32,841	New	+$2.54M	0.74%	29

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

KRS Capital Management's RETA Position: Q3 2023 in Review

KRS Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 27,941 shares — an estimated $2.85M sold.

KRS Capital Management first reported a position in RETA in Q4 2021 and held it in 7 quarters. The position peaked at $2.85M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

KRS Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
KRS Capital Management sold 27,941 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.85M.
KRS Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 7 quarters.
KRS Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.85M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on KRS Capital Management's 13F filing for Q3 2023, filed 19 Oct 2023.